clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT00385827 |
P6099 | clinical trial phase | phase II clinical trial | Q42824440 |
P17 | country | Spain | Q29 |
United States of America | Q30 | ||
Belgium | Q31 | ||
France | Q142 | ||
Austria | Q40 | ||
United Kingdom | Q145 | ||
Germany | Q183 | ||
P582 | end time | 2008-11-01 | |
P921 | main subject | metastatic prostate carcinoma | Q55779807 |
P2899 | minimum age | 18 | |
P1132 | number of participants | 106 | |
P4844 | research intervention | prednisone | Q424972 |
P580 | start time | 2006-11-01 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | A Phase 2, Multicenter, Open-Label Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) in Combination With Mitoxantrone Versus Mitoxantrone in Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC) |
Search more.